Given the aggressive nature of glioblastoma, it is nearly a certainty that all patients will need to be evaluated for potential treatment of recurrent disease. There is currently no definitive standard of care for recurrent glioblastoma. Unlike in other solid…
The cellular origin of glioblastoma is complex. Despite decades of research, the understanding of the cellular, molecular, and pathogenetic architecture of this lethal disease is still evolving. Other chapters discuss the epidemiology, risk factors, associated clinical outcomes, and molecular targeting…
Glioblastoma remains a formidable pathologic entity. Without the tools necessary to make a neurologic diagnosis, early medical and surgical clinicians were likely not only puzzled but also appalled by the downward trajectory of patients affected by this tumor. The development…